Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | CNR1 | P21554 | 2/20 | 0.39 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | GABRP | O00591 | 2/20 | 0.38 |
| ▸ | GABRD | O14764 | 2/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.38 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.38 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.38 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.38 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.38 |
| ▸ | GABRE | P78334 | 2/20 | 0.38 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.38 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27486849 | 0.76 | MEN1 (0.63) | MEN1KMT2ACNR1NTSR1OPRK1 | |
| SCHEMBL30289323 | 0.75 | KMT2A (1.00) | MEN1KMT2ACNR1NTSR1OPRK1 | |
| SCHEMBL8844868 | 0.75 | KMT2A (1.00) | MEN1KMT2ACNR1NTSR1OPRK1 | |
| SCHEMBL9686097 | 0.74 | MEN1 (0.75) | MEN1KMT2ACNR1NTSR1OPRK1 | |
| Ro-24-7429 SCHEMBL29736766 | 0.72 | MEN1 (0.70) | MEN1KMT2ACNR1NTSR1OPRK1 | |
| SCHEMBL9686742 | 0.70 | MEN1 (0.58) | MEN1KMT2ACNR1NTSR1OPRK1 | |
| SCHEMBL27357401 | 0.69 | MEN1 (0.54) | MEN1KMT2ACNR1NTSR1OPRK1 | |
| SCHEMBL9737375 | 0.69 | MEN1 (0.60) | MEN1KMT2ACNR1NTSR1OPRK1 | |
| SCHEMBL15400202 | 0.68 | MEN1 (0.59) | MEN1KMT2AGABRA1GABRA5GABRA3 | |
| SCHEMBL9687273 | 0.67 | MEN1 (0.54) | MEN1KMT2ACNR1NTSR1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8455497-B2 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-06-04 | — | — | US | claimed |
| EP-1686113-B1 | Inhibitors of aspartyl protease | VERTEX PHARMA (US) | 2011-11-23 | — | — | EP | claimed |
| US-20090274650-A1 | INHIBITORS OF ASPARTYL PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED | 2009-11-05 | — | — | US | claimed |
| US-7419967-B2 | Sulfonamide inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-09-02 | — | — | US | claimed |
| EP-1686113-A1 | Inhibitors of aspartyl protease | Vertex Pharmaceuticals Incorporated (US) | 2006-08-02 | — | — | EP | claimed |
| EP-1194404-B1 | INHIBITORS OF ASPARTYL PROTEASE | VERTEX PHARMA (US) | 2006-05-03 | — | — | EP | claimed |
| EP-1027061-B1 | IMINE-FORMING POLYSACCHARIDES, PREPARATION THEREOF AND THE USE THEREOF AS ADJUVANTS AND IMMUNOSTIMULANTS | GALENICA PHARMACEUTICALS INC (US) | 2005-05-25 | — | — | EP | claimed |
| US-6878728-B1 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2005-04-12 | — | — | US | claimed |
| US-20040122000-A1 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED. | 2004-06-24 | — | — | US | claimed |
| US-20020150585-A1 | Use of imine-forming polysaccharides as adjuvants and immunostimulants | GALENICA PHARMACEUTICALS, INC. | 2002-10-17 | — | — | US | claimed |
| CN-1361765-A | Aspartyl protease inhibitors | VERTEX PHARMA (US) | 2002-07-31 | — | — | CN | claimed |
| US-8541600-B2 | 11-aza, 11-thia and 11-oxa sterol compounds and compositions | Harbor Therapeutics, Inc. (US) | 2013-09-24 | — | — | US | disclosed |
| US-8455497-B2 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-06-04 | — | — | US | disclosed |
| US-20120101052-A9 | 15-THIA STEROID COMPOUNDS AND COMPOSITIONS | BIOVIE INC. | 2012-04-26 | — | — | US | disclosed |
| EP-1686113-B1 | Inhibitors of aspartyl protease | VERTEX PHARMA (US) | 2011-11-23 | — | — | EP | disclosed |
| WO-1994005687-A1 | ANTIVIRAL PYRIMIDINE NUCLEOSIDES | UNIVERSITY OF BIRMINGHAM (GB) | 1994-03-17 | — | — | WO | disclosed |
| WO-1994001117-A1 | THERAPEUTIC NUCLEOSIDES | THE WELLCOME FOUNDATION LIMITED (GB) | 1994-01-20 | — | — | WO | disclosed |
| WO-1994001443-A1 | THERAPEUTIC NUCLEOSIDES | THE WELLCOME FOUNDATION LIMITED (GB) | 1994-01-20 | — | — | WO | disclosed |
| WO-1993018765-A1 | INDOLE DERIVATIVES WITH ANTIVIRAL ACTIVITY | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-09-30 | — | — | WO | disclosed |
| WO-1993014103-A1 | THERAPEUTIC NUCLEOSIDES | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122000-A1 | Inhibitors of aspartyl protease | SPINT2, DNPEP, PRSS1 | MEN1 4418/4885KMT2A 864/4885CNR1 4518/4885 |
| US-20120101052-A9 | 15-THIA STEROID COMPOUNDS AND COMPOSITIONS | MPL, THPO, ALOX15 | MEN1 1324/4885KMT2A 2647/4885CNR1 900/4885 |
| US-20090274650-A1 | INHIBITORS OF ASPARTYL PROTEASE | SPINT2, DNPEP, PRSS1 | MEN1 4418/4885KMT2A 864/4885CNR1 4518/4885 |
| US-20020150585-A1 | Use of imine-forming polysaccharides as adjuvants and immunostimulants | TLR1, ICOS, TLR2 | MEN1 1748/4885KMT2A 3401/4885CNR1 551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.